ANI buys some old Merck drugs to challenge Mallinckrodt; Aerie launches glaucoma Phase III;

@FierceBiotech: COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask. More | Follow @FierceBiotech

@JohnCFierce: One win, one loss in Merck's PhIII double header for C diff. Story | Follow @JohnCFierce

@DamianFierce: Filed under Roche Hubris Watch: Reuters article | Follow @DamianFierce

> ANI Pharmaceuticals ($ANIP) paid Merck ($MRK) $75 million for a pair of approved but little-used drugs, planning to relaunch them and compete with Mallinckrodt Pharmaceuticals' ($MNK) Acthar gel. More

> Aerie Pharmaceuticals ($AERI) has kicked off a Phase III trial of Roclatan, its in-development eye drop for glaucoma and ocular hypertension. News

> Boehringer Ingelheim is teaming up with Germany's BioMed X Innovation Center in hopes of identifying the epigenetic regulators of COPD. Item

Medical Device News

@FierceMedDev: ICYMI: Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: Google hires top government brain scientist to probe mental illness. Story | Follow @StacyALawrence

@EmilyWFierce: Some light reading on Otsuka and Proteus' antipsychotic with a built-in sensor. Wired story | Follow @EmilyWFierce

> The NBA's studying wearable monitors. Will players soon wear them during games? More

> CMS proposal to restrict coverage of artificial limbs facing pushback from amputees. Article

Pharma News

@FiercePharma: Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. FierceAnimalHealth report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. Item | Follow @EricPFierce

@CarlyHFierce: Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Hillary Clinton to lay out her plan for cutting drug prices. Article

> Bloomberg: Sanofi, Pfizer mull potential deal for Mexican generics maker Rimsa. More

Animal Health News

> Science think tank calls for global phaseout of antibiotics in agriculture. More

> Merck pioneers injectable vaccine for common pig disease. Item

> VetStem launches trial of drug-free method for preventing hemorrhage in horses. Story

> Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. Article

> ViroVet spins out of Aratana with focus on livestock health. Report

Biotech IT News

> Traders pay SEC $30M to settle newswire hacking case. More

> Google lures NIH mental health chief to life sciences team. News

> Harvard connection helps WuXi NextCODE land Chinese hospital contract. Report

> Microsoft lands cloud genomics infrastructure deal with UC Santa Cruz. Article

> Number of clinical trials to use wearables nears 300. Story

Pharma Marketing News

> More followers and more daily tweeting as Big Pharma's Twitter presence grows. Story

> Sanofi, Pfizer said to be among suitors for Mexico's Rimsa. Item

> Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest. More

> For sale: Orange paint. It might just become your brand's signature. Editor's Corner

> Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.